Skip to main content
TipRanks
Go Ultimate75% OFF

JHS Svendgaard Laboratories Limited (JHS) AI Stock Analysis

1 Followers
IN:JHS

JHS Svendgaard Laboratories Limited

(NSE:JHS)

Select Model
Rating:55Neutral
Price Target:INR 8.50â–²(4.81% Upside)
Action:reiterated
Date:10/06/26

The overall score is constrained by weak financial performance, marked by negative earnings and cash flow despite a strong balance sheet. Positive technical momentum provides a notable uplift, but the lack of profitability and dividends weighs heavily on the valuation.

Positive Factors
Low LeverageVery low leverage reduces solvency pressure and interest-related constraints, giving JHS greater flexibility to manage operating volatility. A balance sheet funded largely by equity can support continued investment in oral-care and private-label activities while limiting dependence on external financing.
Negative Factors
Persistent LossesOngoing net losses and negative operating earnings show that revenue recovery has not yet translated into sustainable profitability. Continued losses can limit internally funded growth, weaken returns on the equity base, and make future performance more dependent on successful execution.

JHS Svendgaard Laboratories Limited (JHS) vs. iShares MSCI India ETF (INDA)

-50%-40%-30%-20%-10%0%10%20%IN:JHS-27.26%INDA-5.34%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
INR 704.49M
Dividend Yield
―
Average Volume (3M)
35.93K
Price to Earnings (P/E)
-57.7
Beta (1Y)
0.48
Revenue Growth
15.61%
EPS Growth
85.89%
Country
India
Employees
235
Sector
General
Sector Strength
55
Industry
Household & Personal Products

JHS Svendgaard Laboratories Limited Business Overview & Revenue Model

Company Description

JHS Svendgaard Laboratories Limited, along with its associated companies, specializes in the manufacturing and sale of a diverse array of oral and dental hygiene products, catering to both adults and children throughout India. Their extensive product...

JHS Svendgaard Laboratories Limited Financial Statement Overview

Summary

Revenue is recovering and losses are narrowing due to cost cuts, but a sharp gross margin decline and persistent negative cash flows indicate significant operational challenges. The strong balance sheet provides a buffer, but overall financial health remains weak.

Income Statement

45Neutral

Balance Sheet

75Positive

Cash Flow

30Negative
Financial statement breakdown
BreakdownTTMMar 2026Mar 2025Mar 2024Mar 2023Mar 2022
Income Statement
Total Revenue1.08B1.02B919.97M698.06M840.82M854.91M
Gross Profit222.32M177.22M309.55M203.55M165.45M201.68M
EBITDA32.15M60.64M-39.92M33.78M-163.82M85.45M
Net Income-11.83M-19.22M-197.44M-40.58M-175.17M-40.52M
Balance Sheet
Total Assets2.16B2.15B2.01B1.97B2.28B2.22B
Cash, Cash Equivalents and Short-Term Investments49.26M191.00M200.16M94.56M386.51M80.19M
Total Debt142.44M148.51M64.58M51.29M155.09M61.82M
Total Liabilities395.40M405.49M284.41M271.70M543.87M269.46M
Stockholders Equity1.76B1.75B1.73B1.70B1.74B1.86B
Cash Flow
Free Cash Flow0-148.91M-157.11M-401.17M89.43M-158.75M
Operating Cash Flow0-20.97M-51.78M-85.84M232.86M-91.36M
Investing Cash Flow0-130.38M-220.18M-217.34M96.77M-46.97M
Financing Cash Flow0121.43M232.97M21.74M-9.00M-16.72M

JHS Svendgaard Laboratories Limited Technical Analysis

Technical Analysis SentimentNegative
Last Price8.11

Price Trends

50DMA8.76Negative
100DMA8.33Negative
200DMA8.66Negative

Market Momentum

MACD-0.23Positive
RSI43.32Neutral
STOCH41.13Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:JHS, the sentiment is Negative. The current price of 8.11 is below the 20-day moving average (MA) of 8.35, below the 50-day MA of 8.76, and below the 200-day MA of 8.66, indicating a bearish trend. The MACD of -0.23 indicates Positive momentum. The RSI at 43.32 is Neutral, neither overbought nor oversold. The STOCH value of 41.13 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for IN:JHS.

JHS Svendgaard Laboratories Limited Peers Comparison

Overall Rating

UnderperformOutperform
Sector (55)

Financial Indicators

IN:JHS against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
IN:EMAMILTDIN:EMAMILTD74OutperformINR 180.99B24.20―2.66%13.15%-1.27%
IN:COLPALIN:COLPAL72OutperformINR 467.00B34.34―2.79%8.72%2.71%
IN:DABURIN:DABUR70OutperformINR 677.92B33.65―2.35%8.94%11.89%
IN:GODREJCPIN:GODREJCP69NeutralINR 909.04B46.27―2.24%12.02%8.49%
IN:HONASAIN:HONASA63NeutralINR 168.93B59.65―0.58%25.70%114.58%
Sector *55Neutral$6.65B3.83-15.92%6.20%10.91%7.18%
IN:JHSIN:JHS55NeutralINR 708.86M-57.70――15.61%85.89%

* General Sector Average

Performance Comparison

-25%0%25%50%75%IN:JHSIN:COLPALIN:DABURIN:EMAMILTDIN:GODREJCPIN:HONASADec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
IN:JHS and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
IN:JHSJHS Svendgaard Laboratories Limited8.11-3.39-29.48%
IN:COLPALColgate-Palmolive (India) Limited1717.00-407.71-19.19%
IN:DABURDabur India Limited382.15-124.12-24.52%
IN:EMAMILTDEmami Limited412.20-86.77-17.39%
IN:GODREJCPGodrej Consumer Products Limited888.20-228.08-20.43%
IN:HONASAHonasa Consumer Limited517.75225.7277.29%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Oct 06, 2026